

Adopted at the Annual General Meeting on: June 4, 2025

Mikkel Viltoft
Chairman

Novozymes Biopharma DK A/S

Krogshøjvej 36, 2880 Bagsværd

CVR No 29 60 35 37

ANNUAL REPORT 2024

Management's Statement

The Executive Board and the Board of Directors have today considered and adopted the Annual Report of Novozymes Biopharma DK A/S for the financial year 1 January - 31 December 2024.

The Annual Report is prepared in accordance with the Danish Financial Statements Act. We consider the accounting policies applied appropriate and the estimates made reasonable.

In our opinion, the Financial Statements give a true and fair view of the financial position at 31 December 2024 of the Company and of the results of the Company operations for 2024.

In our opinion, Management's Review includes a true and fair account of the matters mentioned and describes the most significant risks and elements of uncertainty facing the Company.

We recommend that the Annual Report be adopted at the Annual Shareholders' Meeting.

Bagsværd, June 4, 2025

Executive Board

Mikkel Viltoft

Board of Directors

Lisbet Kragelund
(Chair)

Rainer Lehmann

Mikkel Viltoft

Independent auditor's report

To the shareholders of Novozymes Biopharma DK A/S

Opinion

We have audited the financial statements of Novozymes Biopharma DK A/S for the financial year 1 January – 31 December 2024, which comprise accounting policies, income statement, balance sheet, statement of changes in equity and notes. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2024 and of the results of the Company's operations for the financial year 1 January – 31 December 2024 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

Independent auditor's report

As part of an audit conducted in accordance with ISAs and additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements, or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the Management's review.

Copenhagen, June 4, 2025

EY Godkendt Revisionspartnerselskab

CVR no. 30 70 02 28

Jens Thordahl Nøhr
State Authorised Public Accountant
mne32212

Management Review

The purpose of the company is to operate and invest in research and development, production and trade with biological solutions, including biotechnological products and processes, as well as any business related to this as determined by the Board of Directors. The company strives to operate on a sustainable and responsible way, both financially, socially and environmentally.

For the financial year 2024 the company has realized a profit of DKK 11,543,009 which is line with expectations.

The company proposes to pay ordinary dividend for the financial year of DKK 7,000,000.

Expectations for 2025

Net profit for 2025 is expected to exceed 2024, with a profit after tax expected at DKK 12 - 17 million.

Accounting policies

The Annual Report has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to small enterprises of reporting class B, with some voluntary additions from class C.

Accounting policies are unchanged compared to last year. The financial statements are presented in Danish Kroner (DKK).

Recognition and measurement

The Company's income is recognized in the Annual Report as earned and expenses are recognized when incurred.

Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described below.

Translation policies

Transactions in foreign currencies are translated into DKK at the exchange rates at the dates of transaction. Monetary items in foreign currencies are translated into DKK at the exchange rates at the balance sheet date. Realised as well as unrealised exchange gains and losses are recognised in financial income and expenses in the income statement.

Other operating income

Other operating income includes items of a secondary nature, eg. contingent consideration related to sale of royalty agreements.

Other external expenses

Other external expenses comprise items secondary to the Company's activities, including administration, audit etc.

Financial income and expenses

Financial income and expenses include interest, as well as gains and losses on financial assets, liabilities and transactions in foreign currency.

Tax

Tax on profit for the year which comprises current tax for the year, change in deferred tax as well as any adjustments of previous years is recognised in the income statement. Deferred tax is measured under the balance sheet liability method and comprises all temporary differences between the carrying amount and the tax base of assets and liabilities.

Deferred tax is measured on the basis of applicable tax rules and at the tax rate expected to be effective when the temporary differences are eliminated. Any changes in deferred tax due to changes to the tax rates are recognised in the income statement.

The Company is jointly taxed with the Danish enterprises in the Novo Holdings A/S Group.

The tax of the individual enterprises is fully allocated on the basis of the expected taxable income

Receivables

Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value which normally corresponds to nominal value less any loss allowance for bad debts. Loss allowance for bad debts are determined on the basis of an individual assessment of each receivable.

Financial liabilities

Financial liabilities are measured at amortised cost, substantially corresponding to nominal value. Financial liabilities include trade payables and payables to group enterprises.

Income statement 1. January - 31. December 2024

	Note	<u>2024</u>	<u>2023</u>
		DKK	DKK
Other operating income	1	12,812,478	977,415
Other external expenses	2	(41,304)	(65,652)
Gross profit		<u>12,771,174</u>	<u>911,763</u>
Operating profit		<u>12,771,174</u>	<u>911,763</u>
Financial income	3	2,033,729	18,513,260
Financial expenses	4	(6,175)	(312,569)
Profit before tax		<u>14,798,728</u>	<u>19,112,454</u>
Tax on profit for the year	5	(3,255,719)	(4,204,740)
Net profit for the year		<u>11,543,009</u>	<u>14,907,714</u>
Distribution of profit			
Proposed distribution of profit			
Proposed dividend		7,000,000	60,000,000
Transferred to retained earnings		4,543,009	(45,092,286)
		<u>11,543,009</u>	<u>14,907,714</u>

Balance sheet at December 31, 2024

	Note	2024	2023
		DKK	DKK
Assets			
Receivables from group enterprises	6	27,789,578	75,316,730
Deferred tax assets	7	30,210	53,406
Other receivables		14	42,153
Receivables		27,819,802	75,412,289
Cash at bank and in hand		1,609,728	507,498
Current assets		29,429,530	75,919,787
Assets		29,429,530	75,919,787
Liabilities and equity			
Share capital	8	612,000	612,000
Retained earnings		15,378,189	10,835,180
Proposed dividend		7,000,000	60,000,000
Equity		22,990,189	71,447,180
Trade payables		-	77,500
Payables to group enterprises		-	133,138
Corporation tax		3,232,524	4,043,368
Other payables		3,206,817	218,601
Short-term liabilities		6,439,341	4,472,607
Liabilities and equity		29,429,530	75,919,787
Related parties	9		
Contingent liabilities	10		
Events after the reporting date	11		

Statement of changes in equity

DKK	Share capital	Retained earnings	Proposed dividend	Total
Equity at January 1, 2024	612,000	10,835,180	60,000,000	71,447,180
Net profit for the year	-	11,543,009	-	11,543,009
Paid dividend	-	-	(60,000,000)	(60,000,000)
Proposed dividend	-	(7,000,000)	7,000,000	-
Equity at December 31, 2024	612,000	15,378,189	7,000,000	22,990,189

Notes to the Annual Report

1 Other operating income

Other operating income in 2024 and 2023 is almost entirely related to sale of royalty agreements.

2 Employee costs

There were no employees in the company in 2024 or 2023.

3 Financial income

	<u>2024</u>	<u>2023</u>
	DKK	DKK
Interest income	38,756	24,315
Foreign exchange gain	339,874	11,203,317
Interest on receivables from group enterprises	1,655,099	7,285,628
	<u>2,033,729</u>	<u>18,513,260</u>

4 Financial expenses

Bank charges	(6,175)	(6,214)
Foreign exchange loss	0	(59)
Interest on payables to group enterprises	0	(306,296)
	<u>(6,175)</u>	<u>(312,569)</u>

5 Tax on profit for the year

Tax on profit for the year	(3,232,523)	(4,043,368)
Deferred tax	(23,196)	(161,372)
	<u>(3,255,719)</u>	<u>(4,204,740)</u>

Notes to the Annual Report

6 Receivables from group enterprises

Receivables from group enterprises consist of positive balances on cash pool accounts in the Novozymes A/S cash pool arrangement.

7 Deferred tax

	<u>2024</u>	<u>2023</u>
	DKK	DKK
Deferred tax assets January 1	53,406	214,778
Adjustment for the year	(23,196)	(161,372)
Deferred tax assets December 31	<u>30,210</u>	<u>53,406</u>

Deferred tax assets consist of:

Tangible assets	3,985	5,312
Transaction costs, net	26,225	48,094
Deferred tax December 31	<u>30,210</u>	<u>53,406</u>

8 Share capital

Share capital amounts to DKK 612,000 and consists of 612,000 shares of DKK 1.

9 Related parties

Novozymes Biopharma DK A/S is a wholly-owned subsidiary of Novozymes A/S, Bagsværd and is included in the consolidated financial statements of Novozymes A/S. The ultimate parent company preparing consolidated financial statements is the Novo Nordisk Foundation, Gentofte.

The Novo Nordisk Foundation and its subsidiaries, i.e. the Novo Holdings Group and the Novo Nordisk Group, members of the executive boards of these entities and the management of Novozymes A/S as well as their close family members are considered related parties. Related parties moreover comprise enterprises in which the above-mentioned group of people hold considerable interests.

10 Contingent liabilities

The company is jointly taxed with the Danish companies of the Novo Holdings A/S Group, and is individually liable for the joint taxation liability.

11 Events after the reporting date

No events have occurred after the reporting date of importance to the financial statements for 2024.